News
London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...
1d
GlobalData on MSNGSK’s Blenrep combos approved for multiple myeloma in EUThe combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...
In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab ...
GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...
However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...
The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for ...
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.
The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results